CDK12 and ovarian carcinoma: Ovarian carcinomas with CDK12 loss have reduced expression of multiple HRGs, and CDK12 loss is reported to exhibit synthetic lethality with PARPi (34), though early results of PARPi in CDK12-mutant mPC have identified few responses (15, 16).